Overview

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
2,4-thiazolidinedione
Glyburide
Insulin
Insulin Glargine
Metformin